Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001567619-19-013071
Filing Date
2019-06-07
Accepted
2019-06-07 16:49:59
Documents
1
Period of Report
2019-06-07

Document Format Files

Seq Description Document Type Size
1 FORM 4 doc1.html 4  
1 FORM 4 doc1.xml 4 4044
  Complete submission text file 0001567619-19-013071.txt   5559
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address
Magovcevic Ivana (Reporting) CIK: 0001279281 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37722 | Film No.: 19886568

Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations